Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
Double-blinded, Randomized Trial in Severe Pneumonia Patients With Severe Sepsis Investigating the Safety and Efficacy of Co-administration of Iloprost and Ascending Doses of Eptifibatide Compared to Low-molecular-weight Heparin
Sponsor: Anders Perner
Terminated
Difficulty recruiting patients, company closed down
Other Pneumonia trials with similar outcome
This PHASE2 trial investigates Pneumonia and is currently terminated or withdrawn. Anders Perner leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anders Perner
- Rigshospitalet, Denmark
- Thrombologic ApS
For direct contact, visit the study record on ClinicalTrials.gov .